Arcutis Biotherapeutics Inc (ARQT) stock is down -88.76% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives ARQT stock a score of 33 out of a possible 100.
That rank is influenced by a long-term technical score of 0. ARQT's rank also includes a short-term technical score of 4. ARQT has an Overall Score of 33. Find out what this means to you and get the rest of the rankings on ARQT!